Sonelokimab (M1095)
Hidradenitis Suppurativa (HS)
Key Facts
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a Swiss biotech focused on developing next-generation immunotherapies using its proprietary Nanobody® technology platform. The company's lead asset, sonelokimab, is a first-in-class trivalent Nanobody® targeting IL-17A and IL-17F, with a promising clinical profile in inflammatory skin and joint diseases. Following a successful merger and public listing, MoonLake is advancing sonelokimab into late-stage development, aiming to establish a new standard of care in hidradenitis suppurativa and expand into other autoimmune indications.
View full company profileAbout MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a Swiss biotech focused on developing next-generation immunotherapies using its proprietary Nanobody® technology platform. The company's lead asset, sonelokimab, is a first-in-class trivalent Nanobody® targeting IL-17A and IL-17F, with a promising clinical profile in inflammatory skin and joint diseases. Following a successful merger and public listing, MoonLake is advancing sonelokimab into late-stage development, aiming to establish a new standard of care in hidradenitis suppurativa and expand into other autoimmune indications.
View full company profileAbout MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a Swiss biotech focused on developing next-generation immunotherapies using its proprietary Nanobody® technology platform. The company's lead asset, sonelokimab, is a first-in-class trivalent Nanobody® targeting IL-17A and IL-17F, with a promising clinical profile in inflammatory skin and joint diseases. Following a successful merger and public listing, MoonLake is advancing sonelokimab into late-stage development, aiming to establish a new standard of care in hidradenitis suppurativa and expand into other autoimmune indications.
View full company profileAbout MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a Swiss biotech focused on developing next-generation immunotherapies using its proprietary Nanobody® technology platform. The company's lead asset, sonelokimab, is a first-in-class trivalent Nanobody® targeting IL-17A and IL-17F, with a promising clinical profile in inflammatory skin and joint diseases. Following a successful merger and public listing, MoonLake is advancing sonelokimab into late-stage development, aiming to establish a new standard of care in hidradenitis suppurativa and expand into other autoimmune indications.
View full company profileTherapeutic Areas
Other Hidradenitis Suppurativa (HS) Drugs
| Drug | Company | Phase |
|---|---|---|
| ZORYVE (roflumilast) Foam 0.3% | Arcutis Biotherapeutics | Phase 2 |